The field of induced pluripotent stem cells is barely seven years old, but already three groups are close to launching clinical trials. Ken Garber looks into the prospects and perils.
This is a preview of subscription content, log in via an institution to check access.
Change history
27 June 2013
In the PDF and print versions of this article initially published, the source for the graphic was omitted. It should have read Liheng Wang, New York Stem Cell Foundation. The omission has been corrected in the online PDF.
References
Lister, R. et al. Nature 471, 68–73 (2011).
Mekhoubad, S. et al. Cell Stem Cell 10, 595–609 (2012).
Pomp, O. et al. Cell Stem Cell 9, 156–165 (2011).
Schwartz, S.D. et al. Lancet 379, 713–720 (2012).
Vierbuchen, T. et al. Nature 463, 1035–1041 (2010).
Ieda, M. et al. Cell 142, 375–386 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Inducing translation. Nat Biotechnol 31, 483–486 (2013). https://doi.org/10.1038/nbt.2602
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2602
- Springer Nature America, Inc.
This article is cited by
-
Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes
Stem Cell Research & Therapy (2014)
-
iPS cell technologies: significance and applications to CNS regeneration and disease
Molecular Brain (2014)
-
Tracking gene and cell fate for therapeutic gain
Nature Materials (2014)
-
Efficient and Scalable Expansion of Human Pluripotent Stem Cells Under Clinically Compliant Settings: A View in 2013
Annals of Biomedical Engineering (2014)